MARINUS PHARMACEUTICALS, INC. Quarterly Costs and Expenses in USD from Q1 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Marinus Pharmaceuticals, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2021 to Q2 2024.
  • Marinus Pharmaceuticals, Inc. Costs and Expenses for the quarter ending June 30, 2024 was $40.3M, a 7.39% increase year-over-year.
  • Marinus Pharmaceuticals, Inc. Costs and Expenses for the twelve months ending June 30, 2024 was $165M, a 10.5% increase year-over-year.
  • Marinus Pharmaceuticals, Inc. annual Costs and Expenses for 2023 was $162M, a 17.5% increase from 2022.
  • Marinus Pharmaceuticals, Inc. annual Costs and Expenses for 2022 was $138M, a 23.1% increase from 2021.
  • Marinus Pharmaceuticals, Inc. annual Costs and Expenses for 2021 was $112M, a 61.2% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $165M $40.3M +$2.77M +7.39% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $163M $43.5M +$157K +0.36% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $162M $42.6M +$6.25M +17.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 $156M $39M +$6.55M +20.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $150M $37.5M -$1.04M -2.69% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $151M $43.3M +$12.4M +40.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $138M $36.4M +$7.74M +27% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 $131M $32.4M +$3.16M +10.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $127M $38.6M +$13.2M +51.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $114M $30.9M +$1.93M +6.66% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $112M $28.6M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $29.3M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $25.4M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $29M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.